Rapid screening for safety of donation from donors with central nervous system malignancies

Mingxin Zhu, MD, PhD, Yi Bian, MD, Jipin Jiang, MD, Ting Lei, MD, Kai Shu, MD, PhD

Abstract

With the increasing demand on organ transplants, it has become a common practice to include patients with primary central nervous system (CNS) malignancies as donors given the suggested low probability metastatic spread outside of the CNS. However, an extra-CNS spread of the disease cannot be excluded raising potential risks of cancer transmission from these donors. In order to balance between the risk of donor-derived disease transmission and the curative benefit for the recipient, a careful donor and organ selection is important. We performed a literature research and summarized all reported studies of organ transplants from donors suffering from primary CNS malignancies and determined the risk of tumor transmission to recipients. There were 22 cases of transplant-transmitted CNS tumors onto recipients since 1976. The association risks of cancer transmission were attributed to donor tumor histology, disruption of the blood-brain barrier, cerebrospinal fluid extra-CNS, and false diagnosis of primary intracranial tumor as well as the molecular properties of the primary tumor such as the existence of EGFR-amplification. The association risks and features of CNS tumors transmission recipients indicated that we need to reassess our thresholds for the potential fatal consequences of these donors.

Abbreviations: ANZODR = Australia and New Zealand Organ Donation Registry, CNS = central nervous system, OS = overall survival, UNOS = United Network for Organ Sharing.

Keywords: brain tumor, organ donation, selection, transmission

1. Introduction

In global solid organ transplantation there is an increasing discrepancy of available supply and awaiting receiving patients with over 50,000 patients waiting in the European Union, 120,000 patients waiting in the United States and more than 300,000 waiting patients in China.[1–3] The mismatch between organ resources and demand remains despite of the increasing number of organs derived from deceased donors. In order to expand the pool of organs available for transplantation, it has become a common practice to accept organs from donors suffering from low grade tumors and tumors that have been diagnosed as “low metastatic risk.”[4,5] For decades, patients with primary central nervous system (CNS) tumors are regarded as relatively safe resources for organ donations because of the significantly low incidence rate of extra-CNS spread.[6,7] Recent published guidelines propose that even organs form patients dying of primary CNS tumors including those with high WHO malignancy grade tumors, should be considered for organ donation according to the data from the UK Transplant Registry (UKTR), United Network for Organ Sharing (UNOS) and the Australia and New Zealand Organ Donation Registry (ANZODR).[8–10]

The overall risk of cancer transmission from organ donors with CNS malignancies seems limiting low. However, since 1976, there have been at least some dozens of cases of transmission of primary CNS tumors to transplant recipients.[8,11–13] In early beginning in neuro-oncology, physicians recognized that the general estimates of extra-CNS spread have been quoted less than 1%.[14,15] These studies depend on the fact that the physiological normal brain is anatomically and immunologically privileged and separated as compared to the rest of the body through the existence of the glowering system of blood brain barrier. With the recent technical advances in liquid biopsy, the detection of predictive biomarkers in the blood such as circulating cancer cells, circulating tumor DNA or extracellular vesicles such as epimemous or serum metabolites have emerged.[16–18] Although their importance in establishing extra-cerebral micro-metastatic sites is not mechanistically proven, they propose a potential risk of transmitting the disease to distant organs. As such, Muller and colleagues analyzed 141 patients with glioblastoma and identified circulating tumor cells in 29 cases.[19] Sullivan et al. reported that in 39% of all glioblastoma cases they could detect circulating
tumor cells. It is believed that, despite the high infiltrative and invasive properties of the primary tumor, the tumors are so highly malignant that the patients die before establishing metastatic sites outside the brain. It is unknown whether, besides not having established outside-CNS metastasis, those patients may already be in a stage of systemic tumor spread and thereby oppose a significant risk for disease transmitters in case of organ donation.

This review will discuss the transmission features, association risks, possible mechanism and evaluation protocols of transplantation on the use of organs from donors with primary CNS malignancies which should help the physicians and regulatory authorities to better assess the potential risks with such donor cohorts.

2. Methods

The primary objective of this study was to analyze clinical characteristics, association risks and outcome of cancer transmission on the use of organs from donors with primary brain tumors. First, a system literature search strategy was conducted using PubMed and Web of Science using the following search entries: “central nervous system tumor” AND “organs” AND “transmission” AND “recipients”. Only cases of primary-to-primary tumor transmission was included, cases of development of secondary brain tumors in recipients were excluded in the analyzes. Twenty-two cases of cancer transmission from patients with malignant primary brain tumor published were compiled since 1976. In total, a total of nineteen papers including case reports and reviews were analyzed and included in this study.

From the published reports, the following data were collected:

1. year of publication,
2. age of patient,
3. pathology type of transmission tumor,
4. time to metastasis following transplantation,
5. overall survival (OS) following transplantation,
6. treatment received as categorized by craniotomy and/or radiation and/or chemotherapy, and/ or cerebrospinal fluid shunting.

Donor’s prior risk factors and recipient survival rates were also evaluated. Moreover, the time to metastasis and OS were included in our analysis. The procedure of publication data

Figure 1. Procedure of publication retrieval and exclusion of cases. A PRISMA flow chart for systematic review of cancer transmission from organs of donors with central nervous system malignancies.
3. Results

3.1. Quantification of recorded transmissions of CNS malignancies

Three donor registries have reported their experience: UKTR data showed no case of transmission of donor-transmitted malignancies out of 179 donors with a history of primary intracranial malignancy donating to 448 recipients. ANZODR data reported 151 recipients of 46 donors with primary CNS tumors and no case of transmission of donor malignancy was identified. The UNOS and the Organ procurement and Transplantation Network reported 3 recipients had transmitted malignancies from 642 donors with primary CNS tumors. According the retrospective studies performed by the databases, there were at least hundreds of donors with primary CNS malignancies that provided their organs for organ transplantation. Moreover, there was 22 cases recorded tumor transmission of donor-transmitted malignancies from 1976 to 2014.12,21

By the data of these reports, the grafted organs with primary CNS malignancies transmission included 11 cases of kidney transplantation, 4 cases of liver transplantation, 4 cases of lung transplantation, 1 case of heart transplantation, 1 case of kidney combined with pancreas transplantation and 1 multi-visceral transplantation.

3.2. Clinical course of patients with recorded tumor transmission

The time to metastasis and medium OS as a result of transmission of primary CNS malignancies were analyzed. 22 recipients were transplanted from 16 organ donors with primary CNS malignancies. The average time to metastasis for kidney transplants (n = 7 cases) was 13.2 months post transplantation with an medium OS of 29.6 months. For liver transplant patients (n = 4 cases), three patients died at an average of 7 months post-surgery with a mean time to metastasis of 5.7 months. All lung transplant recipients (n = 4 cases) succumbed due to glioblastoma metastasis. The average OS was 12.5 months (n = 3 recorded cases). One patient was diagnosed with brain cancer metastasis 4 months after receiving multivisceral transplantation and died 6 month post-surgery. Table 1 list OS rates and time to metastasis for all recipients.

3.3. The probability and association risks of CNS malignancies patients

The histologic distribution of tumors identified in the 16 donors predominately identified glioblastomas or gliomas (n = 11 cases), 1 astrocytoma, 1 medulloblastoma, 1 non-hodgkin’s lymphoma, 1meningioma, and 1 pineoblastoma. These 16 donors provided organs to 35 recipients, 22 of whom developed donor transmission tumor or in other words, in 62% of the transplantation of organs a transmission was recorded. The risk of cancer transmission is alarming and caution must be taken when including such cohorts in organ donation campaigns. The information of these donors were provided, and all most of them had at least 1 risk factor, including the diagnosis of high WHO grade brain tumors (n = 14), craniotomy (n = 7), radiation therapy (n = 4) and tumor apoplexy or/ and hemorrhage (n = 3), ventricular shunt (n = 1). The list of risk factors is provided in Table 2.

4. Discussion

Primary CNS malignancies incidence is approximately 5.26 to 7 per 100,000 individuals per year in worldwide.36–38 An average of just more than 7,300 patients aged younger than 65 years old

| Table 1 | Prognosis of recipient transmitted with CNS nerve system malignancies. |
| Reference | Recipient’s age and gender | Transplanted organ | Time to metastasis (months) | Overall survival time (months) | Pathology type of tumor | Year |
| Barnes et al | 61y, M | Kidney | 4.5 | 5 | Malignant Glioma | 1976 |
| Barnes et al | 38y, M | Kidney | 4.5 | >17 | Malignant Glioma | 1976 |
| Lefrancois et al | N/A | Kidney | N/A | N/A | Medulloblastoma | 1987 |
| Lefrancois et al | N/A | Kidney and Pancreas | N/A | N/A | Medulloblastoma | 1987 |
| Lefrancois et al | N/A | Heart | N/A | N/A | Medulloblastoma | 1987 |
| Morse et al | 44y, F | Liver | 8 | 10 | Malignant Glioma | 1990 |
| Koniggrainer et al | N/A | Kidney | N/A | N/A | Lymphoma | 1993 |
| Koniggrainer et al | N/A | Kidney | N/A | N/A | Lymphoma | 1993 |
| Ruiz et al | 48y, F | Kidney | 17 | >33 | Glioblastoma | 1993 |
| Ruiz et al | 23y, M | Kidney | 18 | >33 | Glioblastoma | 1993 |
| Val-Bernal et al | 48y, F | Kidney | 17 | >36 | Glioblastoma | 1993 |
| Colquhoun et al | 32y, M | Kidney | 10 | N/A | Glioblastoma | 1994 |
| Colquhoun et al | 23y, F | Kidney | 10 | N/A | Glioblastoma | 1994 |
| Jonas et al | 28y, F | Liver | 4 | 6 | Glioblastoma | 1996 |
| Bosmans et al | 40y, M | Kidney | 12 | >24 | Meningioma | 1997 |
| Frank et al | 20y, N/A | Liver | N/A | 5 | Glioblastoma | 1998 |
| Armanios et al | 28y, M | Lung | 4 | 4.5 | Glioblastoma | 2004 |
| Chen et al | 57y, M | Lung | 14 | 17 | Glioblastoma | 2008 |
| Fatt et al | 58y, M | Lung | 12 | N/A | Glioblastoma | 2008 |
| Kashyap et al | 54y, M | Liver | 5 | N/A | Malignant Astrocytoma | 2009 |
| Zhao et al | 17m, M | Multivisceral | 4 | 6 | Pineoblastoma | 2012 |
| Nauen et al | 57y, M | Lung | 15 | 16 | Glioblastoma | 2014 |

CNS = central nervous system.
### Table 2
Association risks from organ donors.

| Year | Reference       | Donor's age and gender | Pathology type of CNS tumors | Risk factors | Tumor apoplexy / hemorrhage |
|------|-----------------|------------------------|-----------------------------|--------------|-----------------------------|
| 1976 | Barnes et al    | 45yr, M                | Malignant Glioma            | No           | No                          |
| 1987 | Lefrancois et al| N/A                    | Medulloblastoma             | Yes          | Yes                         |
| 1990 | Morse et al     | 14yr, M                | Malignant Glioma            | No           | No                          |
| 1993 | Konigsrainer et al | 70yr, N/A            | Non-Hodgkin's Lymphoma      | N/A          | N/A                         |
| 1993 | Ruiz et al      | 42yr, M                | Glioblastoma                | No           | Yes                         |
| 1993 | Val-Bernal et al| 42yr, M                | Glioblastoma                | No           | Yes                         |
| 1994 | Colquhoun et al.| 32yr, M                | Glioblastoma                | No           | No                          |
| 1996 | Jonas et al     | 48yr, F                | Glioblastoma                | N/A          | Yes                         |
| 1997 | Bosmans et al   | N/A                    | Meningioma                  | N/A          | N/A                         |
| 1998 | Frank et al     | 42yr, F                | Glioblastoma                | No           | Yes                         |
| 2004 | Armanios et al  | 29yr, M                | Glioblastoma                | No           | Yes                         |
| 2008 | Chen et al      | 47yr, M                | Glioblastoma                | No           | No                          |
| 2008 | Fatt et al      | 58yr, M                | Glioblastoma                | No           | No                          |
| 2009 | Kashyap et al   | 27yr, F                | Astrocytoma                 | N/A          | Yes                         |
| 2012 | Zhao et al      | 14mo, M                | Pineoblastoma               | No           | No                          |
| 2014 | Nauen et al     | N/A                    | Glioblastoma                | N/A          | N/A                         |

Figure 2. The probability of CNS malignancies transmission. The association risks of transmission from donors to recipients has been attributed to donor tumor histology (WHO grade IV), disruption of the blood-brain barrier (craniotomy and chemoradiation therapy), cerebrospinal fluid extra-CNS (ventriculatral and ventriculoperitoneal shunts), as well as natural characteristics of tumor (high level of EGFR-amplified). The more related factors, the more risk of cancer transmission.
die of primary CNS malignancies annually[13,39] and currently there is no risk management in terms of including such diseased patients in the organ donor routine.[5,6] The UNOS/ Organ Procurement Transplantation Network data indicated that annually approximately 50 to 60 patients were procured.[13] Of note, in the United Kingdom, more than four hundreds recipients had received organs from the donors who were died of primary CNS malignancies.[8] These results indicated that the recipients who had been transplanted organs from primary CNS malignancies provided a longer survival when compared with the patients who underwent long-term waiting until transplantation or even none transplantation.[5,40]

Data of UKTR and ANZODR showed that there was no case of donor-derived transmission of metastatic malignancy.[8,9] In contrast, a retrospective review of the Israel Penn International Tumor Registry reported that nearly 23% recipients of organs originating from patients with brain cancer developed donor-transmitted tumors.[41] Furthermore, other institutional data reported the risk of transmission from donors with CNS malignancies to recipient was rare.[13,26,27] Reliable data on the actual percentage of cancer transmission significantly varies in between registries. Our search identified 22 cases of transplant transmitted disease since 1976. A consensus guideline, defining minimum features to be recorded of each organ of a donor with brain cancer and the donor itself, are needed.

Our understanding how genetic apparitions and mutations increases brain cancer malignancy increases rapidly. Molecular subclassification of brain cancer revolutionizes neuropathology, however, the development of adequate treatment options is lagging[42] behind. In the wake of extended molecular profiling of brain cancers during routine clinical diagnostics, our understanding of any genetic association of the tumor to predict for high risk transmission capacities will improve. Current research identified scientific paradigms of tumor stemness and mesenchymal transformation in glioblastoma as key drivers for invasion. It would be interesting to validate any association of elevated stemness markers and mesenchymal differentiation status in the tumor to possible altered frequency of occurrence of extra-CNS transmission.[43,44]

The brain’s lack of lymphatic drainage system and the blood brain barrier represent barriers for extra-CNS spread of tumor cells. However, most cases with cancer transmission were found when the patient had a disrupted of the blood brain barrier due to a consequence of current standard of care treatment or as a result of the tumor growth itself.[13,19,47] In additional, a part of cases develop hydrocephalus which means the presence of ventriculoatrial shunts as well as ventriculoperitoneal shunts could be regarded as a risk factor for cancer transmission.[5,8] Recent reports found that extracranial GBM metastases occur often in the pleura and lungs, liver, bone marrow and regional lymph nodes.[7,46,47] Misdiagnosis of donor brain death due to primary intracranial tumor also has fatal consequences immediately leading to increasing risk of cancer transmission to recipients. Buell et al. previously reported that 23% (14/62) incidences of tumor transmission from organ donors with CNS malignancies.[41] However, in the following studies they found that there were 42 recipients transplanted with organs from donors with misdiagnosed primary CNS tumors. After transplantation these donors were identified with variable tumors including melanoma (23%), renal cell carcinoma (19%), and choriocarcinoma (12%).[48] Misdiagnosis CNS tumors included in the pool of possible donors are associated with high mortality and high transmission rates: Donors without definitive histopathological diagnosis should be avoided for transplantation. Recent studies

---

**Figure 3.** Flow chart for donor selection.
reported that glioblastoma, the most common and aggressive primary malignant brain tumor, may metastasize outside of the CNS system. Accessing via dural vessels to extracranial tissue is considered the most likely path in the development of metastases. Evidence supporting this mechanism based on the pattern of seeding in lymph nodes and the lungs, which are the most frequent affected organs. All of these suggested that either lymphatic or hematologic routes is of importance. However, the infiltrative feature of this aggressive brain cancer seldomly leads to the establishment of extracranial cancer sites, with only about 0.4% to 2.0% of patients developing secondary tumors outside of the brain. [17,49] Seoane et al. discussed several reasons: (i) the cancer cells are not able to thrive on extracranial niches; (ii) the cancer cells might require some brain-specific growth factors; and (iii) the short survival periods of patients with GBM do not allow sufficient time to develop metastasis. [17]

Further reports elucidated that in 20% up to 40% of glioblastoma patients with tumors characterized by EGFR-amplification are positive for the existence of circulating tumor cells in the peripheral blood [17,19,49]. The authors observed that the glioblastoma cells with EGFR copy gain were more prone to disseminate to the bloodstream than other tumor cell clones. These studies indicated that EGFR-amplification in WHO high grade primary brain tumors predict for a higher risk of outside-the-brain metastatic capacity supposedly contributing to extracranial transmission. [50,51]

We hypothesize that the listed “risk factors for cancer transmission” (Fig. 2) could be included and further develop a consensus how to predict the risk of organ transplantation-mediated tumor transmission (Fig. 3).

5. Conclusion

These reports are consistent with those in our study, which demonstrated that the possibility of malignant tumors transmission from CNS tumors donors was very rare. Kauffman et al. reported that, in the United States, the death rate owing to donor-related tumors was extremely low at 0.007%. [40] Our studies emphasize that, although rare, brain cancer transmission through organ donation is possible even if it is rare. With our advances in understanding of molecular subtypes in neuro-oncology, a concise monitoring should aim to define novel “transmission risk markers” which, in conjunction with described “risk markers,” will help to better select safe donor candidates. With increasing demand on organ on increasing global transplantation campaigns, our study should highlight the importance of case-by-case decision making to avoid spreading of otherwise non-infectious lethal diseases.

Author contributions

Data analysis: Mingxin Zhu, Yi Bian, Ting Lei and Kai Shu.
Data curation: Yi Bian, Ting Lei.
Formal analysis: Jipin Jiang.
Investigation: Mingxin Zhu, Jipin Jiang, and Ting Lei
Manuscript preparation: Mingxin Zhu, Yi Bian and Kai Shu
Writing – review & editing: Yi Bian, Ting Lei.

References

[1] Rana A, Gruesser A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg 2015;150:252–9.
[2] Santivane WL, Strand J, Mueller PS, et al. The organ transplant imperative. Mayo Clin Proc 2017;92:940–6.
[3] Sui W, Zheng C, Yang M, et al. Organ donation in China: current status, challenges, and future development. Progress Transplant 2014;24:171–80.
[4] Kaufman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2009;78:1747–51.
[5] Warrens AN, Birch R, Collett DJ, et al. Advising potential recipients on the use of organs from donors with primary central nervous system tumors. Transplantation 2012;93:348–53.
[6] Desai R, Collett D, Watson CJ, et al. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg 2014;101:768–74.
[7] Hamilton JD, Rapp M, Schneider H, et al. Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escape. J Clin Oncol 2014;32:e80–4.
[8] Watson CJ, Roberts R, Wright KA, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant 2010;10:1437–44.
[9] Chui AK, Herbertt K, Wang LS, et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc 1999;31:1266–7.
[10] Engels EA, Castenson D, Pfeiffer RM, et al. Cancers among US organ donors: a comparison of transplant and cancer registry diagnoses. Am J Transplant 2014;14:e1376–82.
[11] Underhill HR, Kitzman JO, Hellwig S, et al. Fragment Length of Circulating Tumor DNA. PLoS genetics 2016;12:e1006162.
[12] Seoane J, De Mattos-Arruda L. Escaping out of the brain. Cancer Discov 2014;4:1299–31.
[13] Giusti I, Di Francesca M, Dolo V. Extracellular vesicles in glioblastoma: role in biological processes and in therapeutic applications. Curr Cancer Drug Targets 2017;17:221–35.
[14] Muller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Trans Med 2014;6:247ra101.
[15] Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Disc 2014;14:1299–309.
[16] Barnes AD, Fox M. Transplantation of tumour with a kidney graft. Br Med J 1976;1:1442–4.
[17] Lefrancois N, Touraine JL, Cantarovich D, et al. Circulating Tumor DNA. PLoS genetics 2016;12:e1006162.
[18] Konigsrainer A, Steurer W, Schumer J, et al. Transmission of non-malignant cancer to recipients of multiorgan donors suffering from primary cerebral neoplasm. Transplantation 1996;50:875–7.
[19] Collignon FP, Holland EC, Feng S. Organ donors with malignant gliomas: an update. Am J Transplant 2004;4:15–21.
[20] Smith DR, Hardman JM, Earle KM. Contiguous glioblastoma multiforme and fibrosarcoma with extracranial metastasis. Cancer 1969;24:270–6.
[21] Cerame MA, Guthikonda M, Kohli CM. Extraneural metastases in gliosarcoma: a case report and review of the literature. Neurosurgery 1985;17:413–8.
[22] Underhill HR, Kitzman JO, Hellwig S, et al. Fragment Length of Circulating Tumor DNA. PLoS genetics 2016;12:e1006162.
[23] Seoane J, De Mattos-Arruda L. Escaping out of the brain. Cancer Discov 2014;4:1299–31.
[24] Giusti I, Di Francesca M, Dolo V. Extracellular vesicles in glioblastoma: role in biological processes and in therapeutic applications. Curr Cancer Drug Targets 2017;17:221–35.
[25] Muller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Trans Med 2014;6:247ra101.
[26] Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Disc 2014;14:1299–309.
[27] Barnes AD, Fox M. Transplantation of tumour with a kidney graft. Br Med J 1976;1:1442–4.
[28] Lefrancois N, Touraine JL, Cantarovich D, et al. Circulating Tumor DNA. PLoS genetics 2016;12:e1006162.
[29] Frank S, Muller J, Bonk C, et al. Transmission of glioblastoma multiforme through liver transplantation. Lancet 1998;352:31.

[30] Armanios MY, Grossman SA, Yang SC, et al. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro Oncol 2004;6:259–63.

[31] Chen H, Shah AS, Girgis RE, et al. Transmission of glioblastoma multiforme after bilateral lung transplantation. J Clin Oncol 2008;26:3284–5.

[32] Fatt MA, Horton KM, Fishman EK. Transmission of metastatic glioblastoma multiforme from donor to lung transplant recipient. J Clin Assist Tomogr 2008;32:407–9.

[33] Kashyap R, Ryan C, Sharma R, et al. Liver grafts from donors with central nervous system tumors: a single-center perspective. Liver Transpl 2009;15:1204–8.

[34] Zhao P, Strohl A, Gonzalez C, et al. Donor transmission of pineoblastoma in a two-yr-old male recipient of a multivisceral transplant: a case report. Pediatr Transplant 2012;16:E110–14.

[35] Nauen DW, Li QK. Cytological diagnosis of metastatic glioblastoma in the pleural effusion of a lung transplant patient. Diagn Cytopathol 2014;42:619–23.

[36] Osmo A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310:1842–50.

[37] Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:683–710.

[38] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.

[39] Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro Oncol 1999;1:205–11.

[40] Kaufman HM, McBride MA, Cherikh WS, et al. Transplant tumor registry: donors with central nervous system tumors. Transplantation 2002;73:579–82.

[41] Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003;76:340–3.

[42] Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature 2018;555:469–74.

[43] Kahlert UD, Joseph JV, Kruyt FAE. EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities. Mol Oncol 2017;11:860–77.

[44] Lahia JD, Mack SC, Mulkearns-Hubert EE, et al. Cancer stem cells in glioblastoma. Genes Dev 2015;29:1203–17.

[45] Je W, Bai J, Li B. An extracranial metastasis of glioblastoma mimicking mucoepidermoid carcinoma. World Neurosurg 2018;116:352–6.

[46] Beauchesne P. Extra-neural metastases of malignant gliomas: myth or reality? Cancers 2011;3:461–77.

[47] Pasquier B, Pasquier D, N’Golet A, et al. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer 1980;45:112–25.

[48] Buell JF, Gross T, Alloway RR, et al. Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality. Transplant Proc 2003;35:583–4.

[49] Oskumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179ra147.

[50] Hou J, Deng Q, Zhou J, et al. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene 2017;36:1134–44.

[51] Lamour V, Henry A, Kroonen J, et al. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. Int J Cancer 2015;137:1047–57.